Overview:

IV to PO conversion has immense potential to benefit patients by preventing unnecessary intravenous therapy associated with risks such as prolonged length of stay, line-associated infections, and excess cost and inconvenience. Although it is often listed as a low hanging fruit for antimicrobial stewardship, there are many nuances to cover. This podcast will discuss special cases, big successes, and gaps in our current understanding of IV to PO conversion.

Speakers:

Monica Mahoney, PharmD, BCPS, BCIDP

Neil Ritchie, PhD, MBCHB, MRCP(UK)

Rebekah Wrenn, PharmD, BCIDP (moderator)